CN211235890U - SARS-CoV-2 detection test paper strip, detection card and detection kit - Google Patents
SARS-CoV-2 detection test paper strip, detection card and detection kit Download PDFInfo
- Publication number
- CN211235890U CN211235890U CN202020673393.3U CN202020673393U CN211235890U CN 211235890 U CN211235890 U CN 211235890U CN 202020673393 U CN202020673393 U CN 202020673393U CN 211235890 U CN211235890 U CN 211235890U
- Authority
- CN
- China
- Prior art keywords
- detection
- pad
- cov
- sars
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The application provides SARS-CoV-2 test paper strip, including consecutive sample pad, combination pad, reaction pad and the pad that absorbs water, the package has the SARS-CoV-2 antigen of colloidal gold mark on the combination pad, and the reaction pad includes detection zone and matter accuse district, and the detection zone is provided with the first detection line of anti-human IgA antibody of peridium, the second detection line of anti-human IgG antibody of peridium and the third detection line of anti-human IgM antibody of peridium. The SARS-CoV-2 detection test strip, the detection card and the detection kit provided by the application are simple to operate, and can carry out detection without professional equipment and professionals; the detection result can appear in a short time, the detection speed is high, and the wide application of the kit is facilitated; the method can be used for simultaneously detecting the specific IgA antibody, the specific IgG antibody and the specific IgM antibody of SARS-CoV-2, effectively reducing false positive, preventing omission detection, having strong specificity and high accuracy, and being beneficial to controlling epidemic situation and preventing diffusion.
Description
Technical Field
The utility model relates to the technical field of biomedicine, in particular to a SARS-CoV-2 detection test strip, a detection card and a detection kit.
Background
The new coronavirus pneumonia (Corona Virus Disease2019, COVID-19) caused by the new coronavirus SARS-CoV-2 has a great influence on the health of people. The world health organization has announced the disease as a global pandemic, but no gold standard has been clinically tested for this infection.
The false negative problem of the existing nucleic acid detection method is serious, the false negative rate of the virus nucleic acid detection in suspected cases is high, and the positive rate of patients with definite diagnosis of COVID-19 is only 30-50%. The sampling link, the nucleic acid extraction link and the qPCR detection link in the nucleic acid detection process are all easy to generate false negative problems. Meanwhile, the nucleic acid detection method is complex, needs to be equipped with professional equipment and professionals for detection, and is not beneficial to the detection of the novel coronavirus pneumonia in the grassroots.
SUMMERY OF THE UTILITY MODEL
In view of the above, the application provides a SARS-CoV-2 detection test strip, a detection card and a detection kit, which have the advantages of simple operation, high detection speed and wide application field; meanwhile, the specific IgA antibody, IgG antibody and IgM antibody of SARS-CoV-2 can be detected simultaneously, false positive is effectively reduced, omission is prevented, and the detection accuracy of COVID-19 is improved.
In a first aspect, the application provides a SARS-CoV-2 test paper strip, including consecutive sample pad, conjugate pad, reaction pad and the pad that absorbs water, the package has colloidal gold mark's SARS-CoV-2 antigen on the conjugate pad, the reaction pad includes detection zone and matter accuse district, the detection zone is provided with the first detection line of anti-human IgA antibody of peridium, the second detection line of anti-human IgG antibody of peridium and the third detection line of anti-human IgM antibody of peridium.
Optionally, the quality control region is provided with a quality control line coated with goat anti-mouse IgG antibody.
Further, the first detection line, the second detection line, the third detection line and the quality control line are parallel to each other, and the lengths and the widths of the first detection line, the second detection line, the third detection line and the quality control line are equal.
Optionally, the reaction pad has first end and the second end of relative setting, the conjugate pad is close to the one end overlap joint of reaction pad is in the first end of reaction pad, the pad that absorbs water is close to the one end overlap joint of reaction pad is in the second end of reaction pad, the sample pad sets up on the conjugate pad.
Furthermore, the lapping length of the combination pad and the reaction pad is 1mm-5mm, and the lapping length of the water absorption pad and the reaction pad is 1mm-5 mm.
Optionally, the sample pad and the combination pad are glass fiber membranes or non-woven fabrics, the water absorption pad is water absorption filter paper, the reaction pad is a nitrocellulose membrane, and the pore diameter of the nitrocellulose membrane is 0.2 μm to 0.45 μm.
Optionally, the SARS-CoV-2 antigen is obtained by gene engineering recombinant expression or purified in cultured virus.
Optionally, the kit further comprises a bottom plate, and the sample pad, the conjugate pad, the reaction pad and the absorbent pad are disposed on the bottom plate.
In a second aspect, the present application provides a SARS-CoV-2 detection card, comprising the first aspect, a SARS-CoV-2 detection test strip, an upper card shell and a lower card shell, wherein the upper card shell and the lower card shell cover to form an accommodation space, the SARS-CoV-2 detection test strip is disposed on the surface of the lower card shell in the accommodation space, a sample addition hole is disposed at a position of the upper card shell corresponding to the sample pad, and an observation window is disposed at a position corresponding to the reaction pad.
In a third aspect, the application provides a SARS-CoV-2 detection kit, comprising a box body and a box cover connected with the box body, wherein the SARS-CoV-2 detection card of the second aspect is arranged in the box body.
Optionally, the device further comprises a colorimetric card or a colloidal gold quantitative reading instrument.
The SARS-CoV-2 detection test strip, the detection card and the detection kit provided by the application have simple operation, and can carry out detection without professional equipment and professionals; the detection result can appear in a short time, the detection speed is high, and the wide application of the kit is facilitated; meanwhile, the SARS-CoV-2 detection test strip, the detection card and the detection kit can simultaneously detect the specific IgA antibody, IgG antibody and IgM antibody of SARS-CoV-2, effectively reduce false positive, prevent omission, have strong specificity, improve the detection accuracy of COVID-19, are beneficial to controlling epidemic situation and prevent diffusion.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. The specific embodiments described herein are merely illustrative of the invention and are not intended to be limiting of the invention.
FIG. 1 is a schematic structural diagram of a SARS-CoV-2 detection test strip provided in an embodiment of the present application.
FIG. 2 is a schematic diagram of a reaction pad in a SARS-CoV-2 detection test strip provided in an embodiment of the present application.
FIG. 3 is a schematic structural diagram of a SARS-CoV-2 detection card according to an embodiment of the present application.
Detailed Description
The technical solutions in the embodiments of the present invention will be described clearly and completely with reference to the accompanying drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments in the present invention, all other embodiments obtained by a person skilled in the art without creative efforts belong to the protection scope of the present invention.
Referring to fig. 1, which is a schematic structural diagram of a SARS-CoV-2 test strip according to an embodiment of the present application, a SARS-CoV-2 test strip 100 includes a sample pad 10, a conjugate pad 20, a reaction pad 30, and a water absorption pad 40, which are connected in sequence, wherein the conjugate pad is coated with a SARS-CoV-2 antigen labeled with colloidal gold. Referring to fig. 2, which is a schematic diagram of a reaction pad according to an embodiment of the present disclosure, a reaction pad 30 includes a detection region and a quality control region, and the detection region is provided with a first detection line 31 coated with an anti-human IgA antibody, a second detection line 32 coated with an anti-human IgG antibody, and a third detection line 33 coated with an anti-human IgM antibody.
In one embodiment of the present application, the sample pad 10 is disposed on the conjugate pad 20 to facilitate the sample to be tested dropped on the sample pad 10 to flow onto the conjugate pad 20.
In one embodiment of the present application, the sample pad 10 has a length of 2cm to 3cm and a width of 2mm to 10 mm.
In one embodiment of the present application, the sample pad 10 is a glass fiber film or a non-woven fabric to facilitate the flow of the sample to be measured.
In the present application, the conjugate pad 20 is coated with a SARS-CoV-2 antigen labeled with colloidal gold. Alternatively, the SARS-CoV-2 antigen is obtained by recombinant expression of genetic engineering or by purification in cultured virus. Further, the SARS-CoV-2 antigen is SARS-CoV-2 Spike protein (Spike protein, S protein) or SARS-CoV-2 Nucleocapsid protein (Nucleocapsid, N protein).
In one embodiment of the present application, the size of the gold colloidal particles is 30nm to 60 nm. Furthermore, the size of the colloidal gold particles is 35nm-45 nm.
In one embodiment of the present invention, a colloidal gold solution is prepared by adding a trisodium citrate solution to a gold chloride solution, a SARS-CoV-2 antigen solution is obtained by mixing and stirring the SARS-CoV-2 antigen-containing solution and the colloidal gold solution, a SARS-CoV-2 antigen solution labeled with colloidal gold is sprayed on the conjugate pad 20, and the conjugate pad 20 coated with the SARS-CoV-2 antigen labeled with colloidal gold is obtained by drying.
In one embodiment of the present application, the conjugate pad 20 has a length of 0.3cm to 2cm and a width of 2mm to 10 mm.
In one embodiment of the present application, the conjugate pad 20 is a glass fiber film or a non-woven fabric.
In one embodiment of the present application, referring to fig. 2, the quality control region is provided with a quality control line 34 coated with goat anti-mouse IgG antibody. In one embodiment, the first detection line 31, the second detection line 32, the third detection line 33 and the quality control line 34 are parallel to each other. In another embodiment, the first sensing lines 31, the second sensing lines 32, the third sensing lines 33, and the quality control lines 34 are equal in length and width. Optionally, the lengths of the first detection line 31, the second detection line 32, the third detection line 33 and the quality control line 34 are 2mm-10mm, and the widths of the first detection line 31, the second detection line 32, the third detection line 33 and the quality control line 34 are 1mm-3 mm.
In one embodiment of the present application, the distance between adjacent detection lines is 1mm to 3 mm. That is, the distance between the first detecting line 31, the second detecting line 32, and the third detecting line 33 and the adjacent detecting lines is 1mm to 3 mm. In one embodiment, referring to fig. 2, the distance between the first sensing lines 31 and the second sensing lines 32 is 1mm to 3mm, and the distance between the second sensing lines 32 and the third sensing lines 33 is 1mm to 3 mm. In another embodiment of the present application, when the reaction pad 30 includes the quality control line 34, the distance between the quality control line 34 and the adjacent detection line is 1mm to 3 mm. In one embodiment, referring to fig. 2, the distance between the quality control line 34 and the third detection line 33 is 1mm to 3 mm. In another embodiment, the pitch between the quality control line 34 and its adjacent detection lines is the same as the pitch between the adjacent detection lines.
In one embodiment of the present application, the reaction pad 30 has a length of 2cm to 3cm and a width of 2mm to 10 mm. Further, the width of the reaction pad 30 is 2mm to 5 mm.
In an embodiment of the present application, of the first, second, and third sensing lines 31, 32, and 33, the first sensing line 31 is disposed at a position closest to the sample pad 10 so that the sample to be measured may first pass through the first sensing line 31.
In one embodiment of the present application, the absorbent pad 40 is absorbent filter paper.
In one embodiment of the present application, the absorbent pad 40 has a length of 1cm to 3cm and a width of 2mm to 10 mm.
In one embodiment of the present application, the reaction pad 30 has a first end and a second end opposite to each other, one end of the conjugate pad 20 close to the reaction pad 30 is overlapped with the first end of the reaction pad 30, and one end of the absorbent pad 40 close to the reaction pad 30 is overlapped with the second end of the reaction pad 30. That is, the bonding pad 20 is partially disposed on the reaction pad 30, the absorbent pad 40 is partially disposed on the reaction pad 30 to facilitate the sample to be tested to flow to the reaction pad 30 through the bonding pad 20, and the absorbent pad 40 is used to absorb the excess water. In one embodiment, the length of the bonding pad 20 overlapping the reaction pad 30 is 1mm-5mm, and the length of the absorbent pad 40 overlapping the reaction pad 30 is 1mm-5 mm. Further, the length of the joint of the combination pad 20 and the reaction pad 30 is 2mm-4mm, and the length of the joint of the absorbent pad 40 and the reaction pad 30 is 2mm-4 mm.
In one embodiment of the present application, the reaction pad 30 is a nitrocellulose membrane having a pore size of 0.2 μm to 0.45 μm.
In one embodiment of the present disclosure, a solution of anti-human IgA antibody, anti-human IgG antibody, anti-human IgM antibody or goat anti-mouse IgG antibody is sprayed on the reaction pad 30, and dried to obtain a corresponding detection line or quality control line.
Referring to FIG. 1, in one embodiment of the present application, the SARS-CoV-2 test strip further comprises a bottom plate 50, and the sample pad 10, the conjugate pad 20, the reaction pad 30 and the absorbent pad 40 are disposed on the bottom plate. In one embodiment, the bottom plate 50 is a polyvinyl chloride plate.
In one embodiment of the present application, a sample to be tested is dropped on the sample pad 10 of the SARS-CoV-2 detection test strip 100, and after several minutes, interpretation is performed according to the color development result, so as to perform qualitative analysis on the sample to be tested. Optionally, the method further comprises diluting the sample to be tested before dropping the sample to be tested. Optionally, the sample to be tested comprises at least one of serum, plasma and whole blood. Specifically, the quality control line 34 is colored, and at least one of the first detection line 31, the second detection line 32 and the third detection line 33 is colored, so that the sample to be detected is judged to contain a corresponding antibody, and further, the SARS-CoV-2 infection of the sample to be detected is judged.
The application detects the specific IgA antibody, the specific IgG antibody and the specific IgM antibody of SARS-CoV-2 simultaneously, effectively reduces false positive, prevents missing detection, has strong specificity and high accuracy, is favorable for controlling epidemic situation and prevents diffusion.
Referring to fig. 3, a schematic structural diagram of a SARS-CoV-2 test card provided in an embodiment of the present application is shown, in which the SARS-CoV-2 test card includes a SARS-CoV-2 test strip 100 of the first aspect, an upper card case 200 and a lower card case 300, the upper card case and the lower card case are covered to form a containing space, the SARS-CoV-2 test strip is disposed on a surface of the lower card case in the containing space, a sample adding hole 201 is disposed at a position of the upper card case corresponding to a sample pad 10, and an observation window 202 is disposed at a position corresponding to a reaction pad 30.
In an embodiment of the present application, the upper card case 200 and the lower card case 300 are detachably coupled. In an embodiment of the present invention, the material of the upper card case 200 and the lower card case 300 is selected conventionally, and may be plastic, rubber, etc., for example, acrylonitrile-butadiene-styrene, and is specifically selected according to actual needs. In one embodiment of the present application, SARS-CoV-2 test strip 100 is adhered to lower housing 300.
In the present application, the sample application hole 201 is a hollow structure, the observation window 202 is a hollow structure or a hollow structure, and all or part of the reaction pad 30 of the SARS-CoV-2 detection test paper strip 100 can be exposed; the shapes of the wells 201 and the observation window 202 are not limited, and may be, but not limited to, circular or square. In an embodiment of the present application, the observation window 202 includes through holes corresponding to the first detection line 31, the second detection line 32, the third detection line 33, and the quality control line 34.
The application also provides a SARS-CoV-2 detection kit, comprising a box body and a box cover connected with the box body, wherein the box body is internally provided with a SARS-CoV-2 detection card of the second aspect.
In one embodiment of the present application, the SARS-CoV-2 detection kit further comprises a sample diluent. Optionally, the sample diluent is phosphate buffered saline.
In one embodiment of the present application, the SARS-CoV-2 detection kit further comprises a colorimetric card or a colloidal gold quantitative reader. In one embodiment, the color strip color change of the detection line corresponding to the anti-human IgA antibody, anti-human IgG antibody or anti-human IgM antibody in a certain concentration range is set in the color chart, and the color chart can be compared with the color chart through the detected color development result to perform semi-quantitative analysis. In another embodiment, the quantitative colloidal gold reader is an optical detection system for quantitative determination of the detection result.
The SARS-CoV-2 detection test strip, the detection card and the detection kit provided by the application have simple operation, and can carry out detection without professional equipment and professionals; the detection result can appear in a short time, the detection speed is high, and the wide application of the kit is facilitated; meanwhile, the SARS-CoV-2 detection test strip, the detection card and the detection kit can simultaneously detect the specific IgA antibody, IgG antibody and IgM antibody of SARS-CoV-2, effectively reduce false positive, prevent omission, have strong specificity, improve the detection accuracy of COVID-19, are beneficial to controlling epidemic situation and prevent diffusion.
The above-mentioned embodiments only represent some embodiments of the present invention, and the description thereof is specific and detailed, but not to be construed as limiting the scope of the present invention. It should be noted that, for those skilled in the art, without departing from the spirit of the present invention, several variations and modifications can be made, which are within the scope of the present invention. Therefore, the protection scope of the present invention should be subject to the appended claims.
Claims (10)
1. The SARS-CoV-2 detection test strip is characterized by comprising a sample pad, a combination pad, a reaction pad and a water absorption pad which are sequentially connected, wherein the combination pad is coated with a SARS-CoV-2 antigen marked by colloidal gold, the reaction pad comprises a detection area and a quality control area, and the detection area is provided with a first detection line coated with an anti-human IgA antibody, a second detection line coated with an anti-human IgG antibody and a third detection line coated with an anti-human IgM antibody.
2. The SARS-CoV-2 detection test strip of claim 1, wherein the quality control region is provided with a quality control line coated with goat anti-mouse IgG antibody.
3. The SARS-CoV-2 detection test strip of claim 2, wherein the first detection line, the second detection line, the third detection line and the quality control line are parallel to each other, and the length and width of the first detection line, the second detection line, the third detection line and the quality control line are equal.
4. The SARS-CoV-2 detection test strip of claim 1, wherein the reaction pad has a first end and a second end disposed opposite, the conjugate pad is configured to overlap the first end of the reaction pad proximate to one end of the reaction pad, the bibulous pad is configured to overlap the second end of the reaction pad proximate to one end of the reaction pad, and the sample pad is disposed on the conjugate pad.
5. The SARS-CoV-2 detection test strip of claim 4, wherein the length of the overlap joint of the conjugate pad and the reaction pad is 1mm-5mm, and the length of the overlap joint of the absorbent pad and the reaction pad is 1mm-5 mm.
6. The SARS-CoV-2 detection test strip of claim 1, wherein the sample pad and the binding pad are glass fiber membrane or non-woven fabric, the water absorption pad is water absorption filter paper, the reaction pad is nitrocellulose membrane, and the pore size of the nitrocellulose membrane is 0.2 μm to 0.45 μm.
7. The SARS-CoV-2 detection test strip of claim 1, wherein the SARS-CoV-2 antigen is obtained by genetic engineering recombinant expression or purified in cultured virus.
8. The SARS-CoV-2 detection test strip of claim 1, further comprising a base plate, the sample pad, the conjugate pad, the reaction pad, and the bibulous pad being disposed on the base plate.
9. A SARS-CoV-2 detection card, comprising the SARS-CoV-2 detection test paper strip of any one of claims 1-8, an upper card shell and a lower card shell, wherein the upper card shell and the lower card shell cover to form a containing space, the SARS-CoV-2 detection test paper strip is arranged on the surface of the lower card shell in the containing space, the upper card shell is provided with a sample adding hole corresponding to the position of the sample pad and is provided with an observation window corresponding to the position of the reaction pad.
10. A SARS-CoV-2 detection kit, comprising a box body and a box cover connected with the box body, wherein the SARS-CoV-2 detection card as claimed in claim 9 is arranged in the box body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020673393.3U CN211235890U (en) | 2020-04-27 | 2020-04-27 | SARS-CoV-2 detection test paper strip, detection card and detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020673393.3U CN211235890U (en) | 2020-04-27 | 2020-04-27 | SARS-CoV-2 detection test paper strip, detection card and detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN211235890U true CN211235890U (en) | 2020-08-11 |
Family
ID=71920235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202020673393.3U Active CN211235890U (en) | 2020-04-27 | 2020-04-27 | SARS-CoV-2 detection test paper strip, detection card and detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN211235890U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111879951A (en) * | 2020-08-17 | 2020-11-03 | 南通伊仕生物技术股份有限公司 | Novel coronavirus IgA/IgG antibody joint inspection immunochromatographic test strip |
| CN112114140A (en) * | 2020-09-11 | 2020-12-22 | 博奥赛斯（天津）生物科技有限公司 | Novel coronavirus IgA antibody colloidal gold detection kit |
| CN112505325A (en) * | 2021-01-22 | 2021-03-16 | 山东康华生物医疗科技股份有限公司 | Test paper strip, test card and kit for detecting SARS-CoV-2 wild strain and mutant strain antigen |
| WO2021217506A1 (en) * | 2020-04-27 | 2021-11-04 | 深圳海博生物技术有限公司 | Application of specific iga and igm in early evaluation of risk of suffering from covid-19 |
-
2020
- 2020-04-27 CN CN202020673393.3U patent/CN211235890U/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021217506A1 (en) * | 2020-04-27 | 2021-11-04 | 深圳海博生物技术有限公司 | Application of specific iga and igm in early evaluation of risk of suffering from covid-19 |
| CN111879951A (en) * | 2020-08-17 | 2020-11-03 | 南通伊仕生物技术股份有限公司 | Novel coronavirus IgA/IgG antibody joint inspection immunochromatographic test strip |
| CN112114140A (en) * | 2020-09-11 | 2020-12-22 | 博奥赛斯（天津）生物科技有限公司 | Novel coronavirus IgA antibody colloidal gold detection kit |
| CN112505325A (en) * | 2021-01-22 | 2021-03-16 | 山东康华生物医疗科技股份有限公司 | Test paper strip, test card and kit for detecting SARS-CoV-2 wild strain and mutant strain antigen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN211235890U (en) | SARS-CoV-2 detection test paper strip, detection card and detection kit | |
| US6372514B1 (en) | Even fluid front for liquid sample on test strip device | |
| US7344893B2 (en) | Immuno-gold lateral flow assay | |
| JP3585933B2 (en) | Opposite component assay device using conduction barrier | |
| AU2020201874B2 (en) | Immunoassay utilizing trapping conjugate | |
| CN111337669A (en) | Novel coronavirus detection test paper and detection method for rapid detection | |
| CN111164095A (en) | Assay methods for improved analyte detection | |
| JP2006091023A (en) | Integrated package holder device for immuno-chromatography assay of flow-through or dipstick type | |
| JP2002522767A (en) | Analytical test apparatus and method | |
| JP2013519899A (en) | Immunoassay device for detecting antibodies and antigens | |
| JPWO2015080286A1 (en) | Detection method using immunochromatography | |
| KR20200102420A (en) | Immunochromatography device | |
| JP3859027B2 (en) | Method for measuring specific substances in nipple discharge | |
| US20210389318A1 (en) | Lateral flow assays for differential isotype detection | |
| US20030027222A1 (en) | Test device for detecting human blood and method of use | |
| CN212483600U (en) | IgA antibody detection test strip, detection card and detection kit for multiple respiratory pathogens | |
| CN113030456A (en) | Detection test strip, detection card and kit for anti-cyclic citrullinated peptide antibody | |
| US20230026892A1 (en) | Lateral flow assay for detecting multiple proteins of a pathogen | |
| JPS63210664A (en) | Dry test piece for device using oxygen demand detection system and detecting method of analytic component in fluid to be inspected | |
| CN111707834A (en) | IgA antibody detection kit for multiple respiratory pathogens | |
| CN212904935U (en) | Device and test strip for immunochromatography detection | |
| CN206740773U (en) | A kind of detection means suitable for HIV antibody of removable chaff interference | |
| JP3713178B2 (en) | Immunoanalyzer for syphilis antibody detection | |
| US12111312B2 (en) | Coronavirus IgG/IgM multiplexed dual path immunoassay device | |
| JPH03233360A (en) | Multi-well stat test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |